echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > Lancet: In the first wave of new coronary pneumonia outbreak, the U.S. SARS-CoV-2 antibody-positive rate was studied.

    Lancet: In the first wave of new coronary pneumonia outbreak, the U.S. SARS-CoV-2 antibody-positive rate was studied.

    • Last Update: 2020-10-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    A routine monthly laboratory examination of the dialysis population and a serotypto-positive assessment of severe acute respiratory syndrome (SARS-Cov-2) in this population can help to produce more realistic, fair and repeatable results.
    In this cross-sectional study, the researchers received samples from approximately 1,300 dialysis facilities across the United States, and by July 2020, the remaining plasma of 28,503 randomly selected adult dialysis patients had been tested for the new coronary pneumonia virus virus (100% sensitivity, 99.8% specificity).
    extracted data on age, gender, race, residence, and facility zip codes from anonymous electronic health records, linking patient-level residence data to cumulative, daily cases, deaths, and nasal swab-testing rates per 100,000 population to assess the positive rates for dialysis and new coronary pneumonia virus in the U.S. population.
    the age, gender, race and ethnicity distribution of the dialysis population in the United States is similar to that of the general population, but the proportion of older persons, men and those living in black and Hispanic neighborhoods is higher. the serum-positive rate of SARS-Cov-2 in the
    sample was 8.0%, and the standard serum-positive rate was 8.3% for dialysis population in the United States and 9.3% for adult populations in the United States.
    the U.S. dialysis population, the region with the lowest serotyt positive rate was in the West, at 3.5 percent, and in the Northeast, at 27.2 percent.
    the sero-positive rate of 9.2 per 100,000 people, which is highly correlated with the number of deaths per 100,000 population (Spearman's ρ-0.77).
    hispanics (OR-3.9) and Hispanic neighborhoods (OR-2.3) were more likely to be seroty-positive than other races.
    sero-positive rate (OR=10.3) for the population of the communities with the highest population density, significantly higher than that of the community residents with the lowest density of one fifth.
    in early March 2020, the positive rate in areas where the embargo was imposed and where work aggregation was reduced by at least 5 per cent (OR=0.4) was significantly lower than in areas where the above measures were only implemented in July.
    study concluded that sars-CoV-2 antibody-positive rates in the adult population of the United States were about 10% in the first wave of the new corona pneumonia pandemic, and that social distance and patient isolation were the most effective means of limiting the spread of the virus, especially in ethnic minorities and densely populated areas.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.